Table 4.

Studies on the impact of body composition on sorafenib outcomes

Outcome/body composition parameter	Correlation	Diagnosis (patients,n)	Reference
Overall survival
Skeletal muscle index	Yes	HCC (232)	Nishikawa et al. [24]
	Yes	HCC (40)	Imai et al. [21]
Yes	HCC (214)	Takada et al. [25]
Yes	HCC (100)	Saeki et al. [19]
No	HCC (52)	Nault et al. [23]
No	HCC (40)	Mir et al. [22]
No	HCC (278)	Labeur et al.
Psoas muscle index	Yes	HCC (93)	Hiraoka et al. [20]
	No	HCC (40)	Yamashima et al. [19]
Muscle density	No	HCC (278)	Labeur et al.
SATI	No	HCC (52)	Nault et al. [23]
	No	HCC (278)	Labeur et al.
VATI	Yes	HCC (52)	Nault et al. [23]
	Yes	HCC (100)	Saeki et al. [19]
No	HCC (278)	Labeur et al.
TATI	No	HCC (278)	Labeur et al.
Visceral fat percentage	No	HCC (278)	Labeur et al.
BMI	No	HCC (40)	Imai et al. [21]
	No	HCC (52)	Nault et al. [23]
No	HCC (278)	Labeur et al.
Muscle + fat (complementary)	Yes	HCC (100)	Saeki et al. [19]
	Yes	HCC (278)	Labeur et al.
Toxicity
Skeletal muscle index	Yes	RCC (55)	Antoun et al. [35]
	Yes	HCC (40)	Mir et al. [22]
Yes	HCC (52)	Nault et al. [23]
No	HCC (214)	Takeda et al. [25]
No	HCC (278)	Labeur et al.
Lean body mass	No	HCC (52)	Nault et al. [23]
Muscle density	No	HCC (278)	Labeur et al.
SATI	No	HCC (40)	Mir et al. [22]
	No	HCC (52)	Nault et al. [23]
No	HCC (278)	Labeur et al.
VATI	No	HCC (40)	Mir et al. [22]
	No	HCC (52)	Nault et al. [23]
No	HCC (278)	Labeur et al.
TATI	No	RCC (55)	Antoun et al. [35]
	No	HCC (40)	Mir et al. [22]
No	HCC (278)	Labeur et al.
Visceral fat percentage	No	HCC (278)	Labeur et al.
BMI	Yes	RCC (55)	Antounet al.[35]
	No	HCC (40)	Miret al.[22]
No	HCC (278)	Labeur et al.
BSA	No	HCC (40)	Miret al. [22]
Muscle + fat (complementary)	No	HCC (278)	Labeur et al.

Reference Labeur et al. refers to the present study. BMI, body mass index; BSA, body surface area; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; SATI, subcutaneous adipose tissue index; SMI, skeletal muscle index; TATI, total adipose tissue index; VATI, visceral adipose tissue index.